Creo Medical

UK-based Creo Medical focuses on the development and commercialisation of minimally invasive electrosurgical devices. Its six products in the flagship CROMA platform have all been CE marked, with five cleared by the FDA. Acquired in 2020, Albyn Medical provides Creo with profitable products and a direct salesforce in Europe.

Equities

Equities by Sector

Sectors

Thematics

Latest

Hybrid Air Vehicles – Redefining air travel and air freight

The humanoid revolution walking your way: How robots are stepping out of science fiction

From gold to gold miners: Extracting higher returns in the current bull run

Audiovisual

Latest

Herantis Pharma – executive interview

Take on Trusts – April 2025

KEFI Gold and Copper – executive interview

About Edison

About Edison

Careers

Creo Medical (AIM: CREO)

Latest Insights

Creo Medical – executive interview

Creo Medical — Refreshed business outlook

Creo Medical — Consumables business divestment concludes

Creo Medical — Consumables business divested in strategic move

Sector

Equity Analyst

Key Management

Creo Medical — FDA nod for UltraSlim

Creo Medical — Potential UltraSlim upside with swift EU pathway

Creo Medical — Detailed half-yearly reflecting Speedboat traction

Creo Medical – executive interview with Craig Gulliford, CEO

Creo Medical — Growth momentum with core strength

Creo Medical — CE extension nearly doubles addressable GI

Creo Medical — NICE to review Speedboat Inject

Creo Medical — New NHS client win for CROMA technology

Creo Medical — Entering phase of accelerating growth inflection

Creo Medical — Albyn Medical stake acquired as wholly owned

Creo Medical — Observational studies to expand capabilities

Creo Medical — Around £30m raised in 48 hours to back growth plans

Creo Medical — Progressing on all fronts

Creo Medical — A rewarding FY22 for core technology arsenal

Creo Medical — Second robotics deal signed

Creo Medical — Building momentum in 2022

Creo Medical — Continued growth momentum in H122

Creo Medical — Solid FY21 followed by robotics deal with Intuitive

Creo Medical — Positive Q122 trading update

Creo — Unlocking the potential of rare cannabinoids

Edison Open House – Creo Medical

Creo Medical — Providing energy for endoscopic surgery